Wolfe Research Downgrades Akero Therapeutics (AKRO) to Peerperform
Tweet Send to a Friend
Wolfe Research analyst Andy Chen downgraded Akero Therapeutics (NASDAQ: AKRO) from Outperform to Peerperform.The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
